Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
AVNS 
Avanos Medical Inc (AVNS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: AVNS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -32.05% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 641.74M USD | Price to earnings Ratio - | 1Y Target Price 17 |
Price to earnings Ratio - | 1Y Target Price 17 | ||
Volume (30-day avg) 527475 | Beta 1.17 | 52 Weeks Range 13.87 - 25.36 | Updated Date 03/30/2025 |
52 Weeks Range 13.87 - 25.36 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -57.01% | Operating Margin (TTM) 4.9% |
Management Effectiveness
Return on Assets (TTM) 1.97% | Return on Equity (TTM) -37.42% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 704243942 | Price to Sales(TTM) 0.93 |
Enterprise Value 704243942 | Price to Sales(TTM) 0.93 | ||
Enterprise Value to Revenue 1.02 | Enterprise Value to EBITDA 17.17 | Shares Outstanding 46003200 | Shares Floating 42189949 |
Shares Outstanding 46003200 | Shares Floating 42189949 | ||
Percent Insiders 3.22 | Percent Institutions 95.97 |
Analyst Ratings
Rating 3.33 | Target Price 22.5 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Avanos Medical Inc
Company Overview
History and Background
Avanos Medical, Inc. (formerly Halyard Health) was spun off from Kimberly-Clark in 2014. The company focuses on medical devices for chronic pain, digestive health, and respiratory health. It has a history of acquiring and divesting businesses to refine its focus on its core segments.
Core Business Areas
- Chronic Pain: Develops and markets pain management solutions, including radiofrequency (RF) ablation technology used to treat chronic pain.
- Digestive Health: Provides enteral feeding tubes and related products used to deliver nutrition to patients who cannot eat or drink adequately.
- Respiratory Health: Offers closed suction systems and airway management products to reduce the risk of ventilator-associated pneumonia (VAP) and other respiratory complications.
Leadership and Structure
Joe Woody serves as the Chief Executive Officer. The company has a board of directors that oversees the overall governance. The organizational structure is divided by the core business areas.
Top Products and Market Share
Key Offerings
- COOLIEF* Cooled Radiofrequency: COOLIEF* is a minimally invasive, radiofrequency ablation technology that uses water-cooled technology to safely treat chronic pain. Market share is estimated to be between 20-25% of the RF ablation market. Competitors include Medtronic, Boston Scientific, and Stryker.
- MIC-KEY* Feeding Tubes: MIC-KEY* is a line of low-profile gastrostomy tubes used for enteral feeding. Avanos estimates they hold ~30% of the market share for these tubes. Competitors include Cardinal Health, Boston Scientific, and Applied Medical Technology.
- BALLARD* Closed Suction Catheters: BALLARD* is a closed suction catheter that removes secretions from the respiratory system without disconnecting the patient from the ventilator. Market share is estimated between 20-25%. Competitors include Smiths Medical, Teleflex, and Medtronic.
Market Dynamics
Industry Overview
The medical device industry is experiencing growth driven by an aging population, increased chronic diseases, and technological advancements. Regulatory approvals and reimbursement policies play a crucial role in the market dynamics.
Positioning
Avanos Medical Inc. is positioned as a focused medical device company with a strong presence in pain management, digestive health, and respiratory health. Its competitive advantage lies in its proprietary technologies and established relationships with healthcare providers.
Total Addressable Market (TAM)
The total addressable market (TAM) for Avanos's products is estimated to be multi-billion dollars, encompassing the global markets for pain management, digestive health, and respiratory health devices. Avanos holds single digit percentage in each segment.
Upturn SWOT Analysis
Strengths
- Focused product portfolio
- Proprietary technologies
- Established market presence
- Strong relationships with healthcare providers
- Global distribution network
Weaknesses
- Reliance on a limited number of key products
- Exposure to reimbursement risks
- Competition from larger medical device companies
- Potential for product liability claims
Opportunities
- Expanding into new geographic markets
- Developing innovative products and technologies
- Acquiring complementary businesses
- Leveraging digital health solutions
Threats
- Increased competition
- Changes in healthcare regulations
- Economic downturns
- Technological obsolescence
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Boston Scientific (BSX)
- Cardinal Health (CAH)
- Smiths Medical (SMITHSGROUP.L)
Competitive Landscape
Avanos has competitive advantages in certain niche segments but faces intense competition from larger, more diversified medical device companies.
Major Acquisitions
Game Ready
- Year: 2018
- Acquisition Price (USD millions): 220
- Strategic Rationale: Expanded the company's chronic pain portfolio with a leading brand in cold and compression therapy.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been impacted by acquisitions, divestitures, and economic climate. It is important to consider the effect these have on the growth of the company.
Future Projections: Analysts predict single-digit revenue growth in the coming years, driven by new product introductions and market expansion.
Recent Initiatives: Recent strategic initiatives include focusing on core business areas, launching new products, and streamlining operations.
Summary
Avanos Medical is a focused medical device company with a solid position in chronic pain, digestive health, and respiratory health. The company's strengths lie in its proprietary technologies and market presence. However, it faces challenges from larger competitors and reimbursement pressures. It needs to capitalize on growth opportunities in new markets and product innovation to improve its performance. It has a mixed history of growth due to restructuring, acquisitions, and divestitures.
Similar Companies
- MDT
- BSX
- CAH
- BDX
Sources and Disclaimers
Data Sources:
- Avanos Medical Inc. SEC Filings
- Company Investor Presentations
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avanos Medical Inc
Exchange NYSE | Headquaters Alpharetta, GA, United States | ||
IPO Launch date 2014-10-21 | Interim CEO, Senior VP & Chief Transformation Officer Mr. Michael C. Greiner CPA | ||
Sector Healthcare | Industry Medical Devices | Full time employees 2227 | Website https://avanos.com |
Full time employees 2227 | Website https://avanos.com | ||
Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides non-opioid pain solutions, including surgical pain and recovery products, which comprise ON-Q and ambIT surgical pain pump, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which provide minimally invasive pain-relieving therapies, such as COOLIEF chronic pain products; OrthogenRx knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. The company markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.